Nanobiotechnology-based drug delivery to the central nervous system
- PMID: 17627131
- DOI: 10.1159/000101884
Nanobiotechnology-based drug delivery to the central nervous system
Abstract
Background: Drug delivery across the blood-brain barrier (BBB) is a major limitation in the treatment of central nervous system (CNS) disorders. Several approaches are being investigated to improve drug delivery across the BBB.
Objective/methods: This review deals with the role of nanobiotechnology in CNS drug delivery. The small size of the nanoparticles enables them to penetrate the BBB and facilitate the delivery of drugs across the barrier. Several mechanisms are involved in this process and various strategies are used based on different types of nanomaterial and combinations with therapeutic agents. Examples are given of the use of liposomes and polymeric nanoparticles.
Results: Nanoparticles can be used as nonviral vectors for CNS gene therapy. Although the use of nanotechnology is expected to reduce the need for invasive procedures for delivery of therapeutics to the CNS, some devices such as implanted catheters and reservoirs will still be needed. Nanomaterials can improve the safety and efficacy of such devices. Nano-engineered probes can deliver drugs at the cellular level using nanofluidic channels. There is some concern about the safety of nanoparticle entry in the brain and this needs to be resolved before human use.
Conclusion: Although there is no approved nanotechnology-based CNS drug as yet that incorporates nanobiotechnology, the future for such developments is promising.
Similar articles
-
Nanobiotechnology-based drug delivery in brain targeting.Curr Pharm Biotechnol. 2013;14(15):1264-74. doi: 10.2174/1389201015666140608143719. Curr Pharm Biotechnol. 2013. PMID: 24910011 Review.
-
Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.Pharmacol Ther. 2004 Oct;104(1):29-45. doi: 10.1016/j.pharmthera.2004.08.001. Pharmacol Ther. 2004. PMID: 15500907 Review.
-
Polymeric nanoparticles for the drug delivery to the central nervous system.Expert Opin Drug Deliv. 2008 Feb;5(2):155-74. doi: 10.1517/17425247.5.2.155. Expert Opin Drug Deliv. 2008. PMID: 18248316 Review.
-
Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.Expert Opin Drug Deliv. 2009 Mar;6(3):211-25. doi: 10.1517/17425240902758188. Expert Opin Drug Deliv. 2009. PMID: 19290842 Review.
-
Drug delivery to the central nervous system: a review.J Pharm Pharm Sci. 2003 May-Aug;6(2):252-73. J Pharm Pharm Sci. 2003. PMID: 12935438 Review.
Cited by
-
Curing epilepsy: progress and future directions.Epilepsy Behav. 2009 Mar;14(3):438-45. doi: 10.1016/j.yebeh.2009.02.036. Epilepsy Behav. 2009. PMID: 19341977 Free PMC article. Review.
-
Addressing barriers in diffuse intrinsic pontine glioma: the transformative role of lipid nanoparticulate drug delivery.ADMET DMPK. 2024 Jul 23;12(3):403-429. doi: 10.5599/admet.2214. eCollection 2024. ADMET DMPK. 2024. PMID: 39091904 Free PMC article. Review.
-
Novel drug delivery strategies for antidepressant active ingredients from natural medicinal plants: the state of the art.J Nanobiotechnology. 2023 Oct 27;21(1):391. doi: 10.1186/s12951-023-02159-9. J Nanobiotechnology. 2023. PMID: 37884969 Free PMC article. Review.
-
Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: At a glance.Front Cell Dev Biol. 2022 Sep 2;10:989471. doi: 10.3389/fcell.2022.989471. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36120565 Free PMC article. Review.
-
Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs.Front Neurosci. 2020 Jun 9;14:494. doi: 10.3389/fnins.2020.00494. eCollection 2020. Front Neurosci. 2020. PMID: 32581676 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources